Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 28, 2011, Pages 3071-3075

  Xie, Cen ^a   Yang, Shilei ^a   Zhong, Dafang ^a   Dai, Xiaojian ^a   Chen, Xiaoyan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Debutyldronedarone; Dronedarone; Liquid chromatography tandem mass spectrometry; Pharmacokinetics

Indexed keywords

ACTIVE METABOLITES; AMIODARONE; ANALYTES; ANTIARRHYTHMIC DRUG; ATMOSPHERIC PRESSURE CHEMICAL IONIZATION; CHROMATOGRAPHIC SEPARATIONS; DEBUTYLDRONEDARONE; DRONEDARONE; GRADIENT ELUTION; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS/MS; LINEAR RANGE; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOWER LIMIT OF QUANTIFICATIONS; MULTIPLE-REACTION MONITORING MODES; ORAL ADMINISTRATION; PHARMACOKINETIC STUDIES; RELATIVE ERRORS; RELATIVE STANDARD DEVIATIONS; SENSITIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; SIMULTANEOUS DETERMINATIONS;

ACETIC ACID; ACETONITRILE; AMMONIUM COMPOUNDS; ATMOSPHERIC IONIZATION; ATMOSPHERIC PRESSURE; CHEMICAL DETECTION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; IODINE; KETONES; LIQUIDS; MASS SPECTROMETRY; METABOLISM; METABOLITES; PHARMACOKINETICS; PLASMA (HUMAN);

CHROMATOGRAPHY;

ACETONITRILE; AMIODARONE; DEBUTYLDRONEDARONE; DRONEDARONE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; ATMOSPHERIC PRESSURE; CHEMICAL REACTION; COLUMN CHROMATOGRAPHY; DRUG DETERMINATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IONIZATION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; TANDEM MASS SPECTROMETRY;

EID: 80053573931     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.09.004     Document Type: Article

References (10)

1. Naccarelli G.V., Wolbrette D.L., Dell'Orfano J.T., et al. Clin. Cardiol. 2000, 23:73.
2. Van Beeren H.C., Jong W.H., Kaptein E., et al. Endocrinology 2003, 144:552.
3. Singh B.N., Connolly S.J., Crijns H.J., et al. N. Engl. J. Med. 2007, 357:987.
4. Hohnloser S.H., Crijns H.J., van Eickels M., et al. N. Engl. J. Med. 2009, 360:668.
5. USFDA, 2011, (accessed 19 June, 2011). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM134981.pdf.
6. USFDA, 2008, (accessed 19 June, 2011). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory%20Information/Guidances/ucm079266.pdf.
7. Boldermana R.W., Hermansb J.J., Maessena J.G. J. Chromatogr. B 2009, 877:1727.
8. Damy T., Pousset F., Caplain H., et al. Clin. Pharmacol. 2004, 18:113.
9. Yang S., Dai X., Tang X., et al. Chin. J. Pharma 2011, 42:7.
10. USFDA, 2001, (accessed 19 June, 2011). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory%20Information/Guidances/ucm070107.pdf.